HyperAcute cellular immunotherapy platform
E1249866
UNEXPLORED
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| HyperAcute cellular immunotherapy platform canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T17093457 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: HyperAcute cellular immunotherapy platform Context triple: [NewLink Genetics, hasTechnology, HyperAcute cellular immunotherapy platform]
-
A.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Research Center for Immunotherapy
The Research Center for Immunotherapy is a specialized institute at Johannes Gutenberg University Mainz dedicated to advancing understanding and development of immune-based treatments for diseases such as cancer and autoimmune disorders.
-
E.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: HyperAcute cellular immunotherapy platform Target entity description: HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
A.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Research Center for Immunotherapy
The Research Center for Immunotherapy is a specialized institute at Johannes Gutenberg University Mainz dedicated to advancing understanding and development of immune-based treatments for diseases such as cancer and autoimmune disorders.
-
E.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.